


## Fmoc-MMAE

<b>Cat. No.:</b>	HY-78933
<b>CAS No.:</b>	474645-26-6
<b>Molecular Formula:</b>	C <sub>54</sub> H <sub>77</sub> N <sub>5</sub> O <sub>9</sub>
<b>Molecular Weight:</b>	940.22
<b>Target:</b>	Microtubule/Tubulin; ADC Cytotoxin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	4°C, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 45 mg/mL (47.86 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.0636 mL	5.3179 mL	10.6358 mL
	5 mM	0.2127 mL	1.0636 mL	2.1272 mL
	10 mM	0.1064 mL	0.5318 mL	1.0636 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Auristatin

### REFERENCES

[1]. Pan D, et al. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. *Cancer Med.* 2020;9(24):9529-9540.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA